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In an effort to identify de novo genetic variants that contribute to the overall risk of autism, the Simons Foun-
dation Autism Research Initiative (SFARI) has gathered a unique sample called the Simons Simplex Collec-
tion (SSC). More than 2000 families have been evaluated to date. On average, probands in the current sample
exhibit moderate to severe autistic symptoms with relatively little intellectual disability. An interactive data-
base has been created to facilitate correlations between clinical, genetic, and neurobiological data.Introduction
Autism is a developmental disorder char-
acterized primarily by alterations in recip-
rocal social interaction and restricted
interests. Abnormal repetitive behaviors
and verbal communication, and various
comorbid conditions, also contribute to
the broad autism phenotype. Using
increasingly expansive definitions, the re-
ported prevalence of autism has in-
creased in recent decades and now
approaches the astonishing figure of 1%
of the American population. Despite
heightened public awareness and
concern, causes of autism remain
obscure. But there can be no doubt that
genetics plays a major role.
Driven by remarkable advances in
genome science, the search for genes
that enhance the risk of autism has esca-
lated over the past 5 years. However,
during the same time period, it has
become clear that the genetic landscape
of autism is complex, with many genes
contributing to the broad autism pheno-
type (Abrahams and Geschwind, 2008;
Cook and Scherer, 2008).
Most cases of autism are sporadic, so
one promising approach to the genetic
complexity is to search for genetic vari-
ants in autistic individuals that are not
present in their unaffected parents and
siblings. Recent data indicate that
probands in such ‘‘simplex’’ families may
exhibit submicroscopic deletions and
duplications and that the same copy
number variants (CNVs) are not present
in parents or siblings. Unaffected siblings
in simplex families offer ideal controls for
identification of de novo CNVs that are192 Neuron 68, October 21, 2010 ª2010 Elsetruly associated with autism. Case-
control studies are less compelling in
this regard.
The de novo CNVs discovered to date
are rare, occurring in 1% or less of autistic
individuals. But there may be many rele-
vant CNVs, and all together, they may
account for a significant fraction of idio-
pathic autism (Christian et al., 2008; Sebat
et al., 2007; Weiss et al., 2008). A system-
atic search should pay dividends but
more simplex families are needed.
The Simons Foundation Autism
Research Initiative (SFARI), urged on by
Michael Wigler at the Cold Spring Harbor
Laboratory and by others, embarked on
an effort to recruit and carefully evaluate
more than 2000 simplex families. We
emphasize careful evaluation because
the autism phenotype is often not
precisely defined at the extremes even
though meaningful phenotype/genotype
correlations depend on accurate clinical
data. Here we describe how the SSC
was organized, our methods for ensuring
data quality, and our plans for the future.
The SSC extends other autism genetic
repositories such as the Autism Genetic
Resource Exchange (Geschwind et al.,
2001), the Autism Genome Project, and
the NIMH repository. These important
data sets differ from the SSC in how the
data were collected and curated, and in
the exclusion criteria employed.
Recruitment of Families
It seemed reasonable that evaluation of
families at clinics already serving children
with autism and their families would opti-
mize recruitment, dissemination of bestvier Inc.practices, and, ultimately, the quality of
clinical data. Alliance with providers at
a clinic would also optimize chances for
follow up studies. Therefore, a coalition
was formed of clinics located at Michigan,
Yale, Emory, Columbia, Vanderbilt, McGill
Washington, and Harvard Universities
(Children’s Hospital of Boston), and at
the Universities of Washington, Illinois
(Chicago), Missouri, UCLA, and the Baylor
College of Medicine.
A summary to date of the SSC is shown
in Table 1. The great majority (>80%) of
families include at least one unaffected
sibling. The simplex architecture is less
certain in trios in which the proband is
the only child than it is in quads.
Criteria were defined for case validation
and each site was asked to provide at
least 20 validated families per quarter.
To ensure that the SSC population was
independent of earlier cohorts, efforts
were made to recruit new families. It was
not easy to find new families who met all
of our stringent inclusion criteria (see
below). Therefore, recruitment tools
were developed that included partner-
ships with local service providers and
parent and advocacy groups, and web
postings and radio and television ads.
Children are exposed to risks that are
greater than risks incurred in activities of
daily living when they participate in an
evaluation study like the SSC. Therefore
parents consented and children assented
as required by each local institutional
review board. To protect the privacy of
participants, Global Unique Identifiers
(GUIDs) were constructed from personal
information using an algorithm devised in
Table 1. SSC Sample by Family Type and Gender
Quads
Proband Trios Male Sibling Female Sibling Total
Male 306 617 708 1631
Female 52 92 112 256
Total 358 709 820 1887
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(Johnson et al., 2010). Each clinic retained
personal identifiers on site and trans-
mitted deidentified GUIDs to a central
database (see below).
WithGUIDsassigned, individuals canbe
linked anonymously to other databases
including theNational Database for Autism
Research (NDAR) maintained by the
NIMH. They can also be enrolled in follow
up studies including new projects con-
ducted by different investigators without
concern about duplication or overlap.
The clinic design maximizes the
success of longitudinal studies. They are
important because a single slice in time,
no matter how accurate the data, cannot
give an accurate prediction of autism
over the lifespan. Follow up studies will
become even more important as clinical,
genetic, and neurobiological data accu-
mulate.
Infrastructure
A geneticist and a clinical psychologist
were appointed as coprincipal investiga-
tors at each site. The principal psycholo-
gist evaluated families and supervised
other clinical psychologists on the site
team. Each site also included a project
coordinator and a data manager. Best
practices, rates of accrual, and recent
advances in autism science were shared
in monthly phone calls that included
members of each site team and members
of the SFARI staff. Information was also
shared in site visits and at biannual group
meetings.
All together, these efforts created
a sense of shared purpose and they are,
in large part, responsible for our success
to date. As shown in Figure 1, we
achieved a high rate of accrual that has
been maintained throughout the study.
Evaluation of Probands and
Families
Probandswere evaluatedwith a battery of
diagnostic measures, including theAutism Diagnostic Interview – Revised
(ADI-R) (Lord et al., 1994) and the Autism
Diagnostic Observation Schedule (ADOS)
(Lord et al., 2000). Other instruments
provided additional measures of the
core features of autism, as well as of
intellectual ability (verbal and non-
verbal), adaptive behavior, emotional
and behavior problems, motor function,
and language. A description of instru-
ments employed can be found at https://
sfari.org/ssc-instruments. A comprehen-
sive family medical history was obtained
that included the proband’s prenatal and
perinatal history, developmental mile-
stones, immunizations, medications, die-
tary supplements, and common behav-
ioral treatments. Emphasis was placed
on common ‘‘comorbidities’’ including
gastrointestinal complaints, sleep irregu-
larities, and seizures. In addition, ques-
tions were asked about genetic, autoim-
mune, and psychiatric disorders in
members of the extended family.
Probands were excluded who were
younger than 4 years of age or older than
18. Probands were also excluded for
conditions thatmight compromise the val-
idity of diagnostic instruments, such as
nonverbal mental age below 18 months,
severe neurological deficits, birth trauma,
perinatal complications, or genetic evi-
dence of fragile X or Down syndromes.
A complete description of exclusion/inclu-
sion criteria can be found at http://sfari.
org. The four most common reasons for
exclusion were as follows: candidate did
not meet criteria for Autism Spectrum
Disorder (ASD); primary relatives were on
the autism spectrum;medically significant
perinatal incidents; and low mental age.
Table 2 shows descriptive data for the
first 1887 probands. Measures of adap-
tive function, behavior-emotional prob-
lems, and symptoms of autism were
examined in parents and siblings as well
as probands.
Thus, the SSC represents a unique,
well-described sample of able childrenNeuron 68and adolescents with relatively severe
ASD, as indicated by ADI-R and ADOS
Calibrated Severity Scores (Gotham
et al., 2009).
Reliability of Data
To maximize the consistency of clinical
observations across sites, each clinician
was trained in administration of the
ADOS and ADI-R to achieve research reli-
ability as judged by expert clinicians.
Most clinicians who had not previously
received research training required
4–6 months of practice. Videotapes of
interviews were exchanged to ensure
that reliability requirements were met
and maintained throughout the study.
A team of consultants composed of
four clinical psychologists from the
University of Michigan assisted sites
with training and case validation using
logical checks of variables across
measures that would signal inconsis-
tencies in coding or data entry. Error rates
were very low, averaging less than
0.50 errors/1000 data points. Most errors
could be corrected immediately, resulting
in an unusually clean data set for a multi-
site study of this size.
Our emphasis on rigorous training and
careful data curation paid off: scores
based on direct observation or on ques-
tionnaires obtained at the various sites
fell within a narrow range. One site devi-
ated significantly from the overall mean,
so families at that site will be reevaluated.
Despite agreement in scores on standard-
ized measures, consistent differences
between sites in overall clinical impres-
sion were reported. With the same scores
on standardized tests, some observers
preferred the label Autism, while others
preferred Asperger syndrome or Perva-
sive Developmental Disorder-Not Other-
wise Specified. Thus, traditional ASD
diagnostic subcategories were not useful
in describing SSC probands. Our findings
are reflected in the new classification,
Autism Spectrum Disorders, proposed
for the next version of the Diagnostic
and Statistical Manual V of the American
Psychiatric Association.
Resources Available to the
Research Community
A blood sample was collected from each
study participant. DNA was extracted
from blood cells, plasma was stored,, October 21, 2010 ª2010 Elsevier Inc. 193
Figure 1. Accrual Rates by Quarter
Validated families with whole-blood DNA. The accumulation of
lymphoblastoid cell lines paralleled this curve with a short delay.
C = current as of submission.
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from transformed lymphoblasts at
the Rutgers University Cell and
DNA Repository (RUCDR). The
RUCDR also analyzed each
sample to confirm parentage and
gender and to rule out the fragile
X syndrome.
In collaboration with Prome-
theus Research LLC, SFARI inves-
tigators developed a software
platform, SFARI Base, to support
data acquisition, validation, and
distribution. Notable innovations
include a query tool for selecting
a defined cohort, measures of
interest, and biological speci-
mens. A Data Navigator displays
all data from all individuals as
well as correlations among the
variables. In addition, summary
variables that aggregate multiple
raw variables into a single valueare available. They are intended to help
create links between clinical, genetic,
and neurobiological data, and they will
be updated regularly depending on user
demand. Summary variables are particu-
larly useful when dealing with multiple
informants and overlapping constructs.
Data on CNVs from the first whole-
genome scans of SSC participants based
on NimbleGen chips and on Illumina
chips are available at https://sfari.org/
sfari-base. Investigators can also obtain
the SSC clinical data set and relevantTable 2. Proband Age and Standardized Tes
Chronological age (years)
Verbal IQ*
Nonverbal IQ
ADI-R Social interaction
Communication – verbala
Communication – nonverbal
Restricted/repetitive behaviors
ADOS Calibrated severity scoresb
Social + communication
Social affect2
Restricted/repetitive behaviors
Vineland
n = 1877.
a The verbal domain is not calculated for participa
bCalibrated Severity Scores and Social Affect tota
194 Neuron 68, October 21, 2010 ª2010 ElseDNA samples by registering at https://
sfari.org/sfari-base.
Looking Ahead
Our initial aim in creating the SSC was to
facilitate chip-based searches for rare,
highly penetrant CNVs. Additional families
will be evaluated in the coming year, and
high-throughput DNA sequencing will be
pursued to identify small de novo variants
below the resolution of existing chips, and
single nucleotide polymorphisms that are
candidate autism risk factors. As the SSCt Scores by Gender
Males (n = 1631)
Mean (SD) Range
8.91 (3.48) 4–18
80.44 (30.03) 5–153
87.58 (24.75) 9–161
19.96 (5.68) 8–30
16.30 (4.21) 6–26
9.07 (3.39) 0–14
6.55 (2.53) 0–12
7.39 (1.71) 4–10
13.12 (4.19) 5–24
10.89 (4.02) 3–20
3.94 (2.06) 0–8
74.49 (11.59) 27–115
nts who receive a 1 or a 2 on ADI-R item 30; therefore, n =
ls are not calculated for Module 4; therefore, n = 1580 ma
vier Inc.grows, inherited variants andmore
common variants of smaller effect
may be discovered as well.
To determine which de novo
variants are truly autism risk
factors, several questions must
be asked. Is the variant recurrent?
Does it disrupt gene function,
directly or indirectly, perhaps via
regulatory elements in noncoding
regions? How many genes are
involved? Does it produce a rele-
vant behavioral, physiological, or
anatomical phenotype in mouse
models or in other species? Does
genetic imprinting in critical brain
regions impact the manifestation
of candidate genetic variants?
These questions have been
answered satisfactorily for only a
handful of genes. A list of about
200 candidates culled from the
literature by S. Basu of MindspecInc. appears at http://gene.sfari.org/. A
curated list in which the genes are rank
ordered by stringent criteria will appear
at that web site in the near future.
Comments will be invited in the hopes
that this can be made a collaborative,
dynamic effort.
Despite the complexity of autism
genetics, there is reason for optimism
even in the short term. The multiplicity of
genetic variants may lead to one or
a few common signaling pathways. The
system of synaptic membrane proteinsFemales (n = 256)
Mean (SD) Range
9.11 (3.69) 4–18
76.03 (32.40) 11–167
79.16 (26.15) 23–148
20.10 (6.13) 8–30
16.35 (4.36) 6–26
8.96 (3.77) 1–14
6.20 (2.48) 0–12
7.34 (1.74) 4–10
13.59 (4.63) 4–24
11.37 (4.27) 3–20
3.86 (2.13) 0–8
71.36 (12.13) 32–101
1470 males, 230 females.
les, 247 females.
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their distribution and function is a prom-
ising example. This pathway must
regulate the delicate balance between
synaptic excitation and inhibition in
crucial neural circuits that are active in
the social brain. The same pathway is
likely involved in forms of synaptic
plasticity that underlie the ability to learn
and alter behavior. Thus, beyond the level
of molecular neurobiology, genetic vari-
ants may provide clues about autistic
behaviors.
As signaling pathways are explored, the
genetic variants may lead to biomarkers
that will greatly facilitate detailed pheno-
type/genotype correlations. This is partic-
ularly the case as longitudinal studies
progress, as detailed medical information
is gathered, and as advances in neuroi-
maging and cognitive neuroscience
suggest new assays of social cognition.
Convincing genetic variants will also
allow the converse approach: more
detailed genotype/phenotype correlation.
A new effort called the Simons Variation in
Individuals Project (Simons VIP) is
underway under the guidance of W.
Chung at Columbia and J. Spiro at the
Simons Foundation. Deletions and dupli-
cations at chromosome 16p 11.2, one
of the most recurrent and, hence
convincing, autism-associated CNVs,
will be the first variant studied. Indi-viduals identified by clinical laboratories
throughout the country and by other sour-
ceswill be invited for detailed clinical eval-
uation at one of three sites. Lessons
learned in assembling the SSC will be
valuable in operationalizing the Simons
VIP.
In sum, the SSC illustrates how plan-
ning and cooperation can lead to the rapid
accumulation of high-quality data from
a large number of families gathered at
geographically dispersed sites. It has
already triggered an enormous amount
of research. We anticipate that the SSC
will be an extraordinary resource for
autism researchers, for those interested
in other neuropsychiatric disorders that
share features with autism, and, indeed,
for all neuroscientists.ACKNOWLEDGMENTS
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